Skip to main content
. 2014 Dec;10(4):229–235.

Figure 4.

Figure 4

The relation between changes in serum ADAM17 level and clinical responses to ABT therapy. Panel A: A significant reduction in serum ADAM17 level was observed in the responsive group (n=21, *p<0.05), but not in the unresponsive group. Panel B: Serum ADAM17 levels were significantly decreased in the group achieved clinical remission (n=10, *p<0.05) after 24 weeks of ABT therapy.